Here's What the Media Missed During the FDA's CBD Hearings

On Friday, May 31, the U.S. Food & Drug Administration held its first-ever hearings on cannabidiol, or CBD. The event didn't exactly slip under the radar... Headlines ranged from Jezebel's laughably sensationalistic "Is CBD Over?" to The New York Times' more serious "Cannabis Companies Push FDA to Ease Rules on CBD Products." This hearing, an all-day affair that lasted from 8 a.m. on Friday till 6 p.m., deserved every second of the coverage it received. But there's one thing we didn't see covered... And it's likely exactly the thing needed to push the FDA in the right direction when it comes to CBD regulation... Tags: Stocks To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2019 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Here's What the Media Missed During the FDA's CBD Hearings appeared first on Money Morning - We Make Investing Profitable .